Hostname: page-component-74656f9884-8r8nv Total loading time: 0 Render date: 2026-11-07T22:05:53.540Z Has data issue: false hasContentIssue false

The Study of the Antisaccade Performance and Contingent Negative Variation Characteristics in First-Episode and Chronic Schizophrenia Patients

Published online by Cambridge University Press:  26 October 2017

Anna V. Kirenskaya*
Affiliation:
V.Serbsky Federal Medical Research Centre for Psychiatry and Narcology (Russia)
Andrej A. Tkachenco
Affiliation:
V.Serbsky Federal Medical Research Centre for Psychiatry and Narcology (Russia)
Vladimir Yu. Novototsky-Vlasov
Affiliation:
V.Serbsky Federal Medical Research Centre for Psychiatry and Narcology (Russia)
*
*Correspondence concerning this article should be addressed to Anna Kirenskaya. Federal State Budgetary Institution “V.Serbsky Federal Medical Research Centre for Psychiatry and Narcology” of the Ministry of Health of the Russian Federation. Kropotkinsky per. 23. 119992. Moscow (Russia). Phone: +74956374622. E-mail: neuro11@yandex.ru
Rights & Permissions [Opens in a new window]

Abstract

The study tested whether the antisaccade (AS) performance and Contingent Negative Variation (CNV) measures differed between the first-episode and chronic patients to provide the evidence of PFC progressive functional deterioration. Subjects included 15 first-episode and 20 chronic schizophrenic patients (with the duration of illness more than 5 years), and 21 control subjects. The first-episode and chronic patients had significantly elevated error percent (p < .05, effect size 1.10 and p < .001, effect size 1.25), increased AS latencies (p < .01, effect size 1.18 and p < .001, effect size 1.69), and increased latencies variability (p < .01, effect size 1.52 and p < .001, effect size 1.37) compared to controls. Chronic patients had marginally significant increase of the response latency (p = .086, effect size .78) and latency variability (p < .099, effect size .63) compared to first-episode ones. Results of CNV analysis revealed that chronic patients only exhibited robustly declined frontal CNV amplitude at Fz (p < .05, effect size .70), F3 (p < .05, effect size .88), and F4 (p < .05, effect size .71) sites compared to controls. The obtained results might be related to specific changes in prefrontal cortex function over the course of schizophrenia.

Information

Type
Research Article
Copyright
Copyright © Universidad Complutense de Madrid and Colegio Oficial de Psicólogos de Madrid 2017 
Figure 0

Table 1. Demographic and clinical characteristics for first-episode and chronic schizophrenia patients, and healthy subjects

Figure 1

Figure 1. Experimental paradigm and examples of EOG recording. A. Experimental design of the visual stimuli presentation. Dark circle – the stimulus is “on”, light circle – the stimulus is “off”. B. Example of EOG recording. FP – fixation point PT – peripheral target EOG - electrooculogram.

Figure 2

Figure 2. Grand average curves at the midline frontal and parietal sites in the groups of control subjects and schizophrenic patients. PT - peripheral target onset.

Figure 3

Table 2. Saccade characteristics

Figure 4

Figure 3. Scalp potential maps of negative shift. Negative potentials are depicted in gray, positive potentials - in white.

Figure 5

Figure 4. Average frontal CNV amplitudes during the 1st and 2nd analysis intervals. Level of significance: + - p<0.1, * - p<0.05. Level of significance is presented in comparison to chronic patients group.

Figure 6

Table 3. PANSS scores differences between first-episode and chronic schizophrenic patients

Figure 7

Table 4. Significant Spearman’s correlations (R) between PANSS scales and amplitudes of slow potentials in the first-episode patients group

Figure 8

Table 5. Significant Spearman’s correlations (R) between PANSS scales and amplitudes of slow potentials in the chronic patients group